TERAPIA COMBINADA DE CARVACROL COM TREINAMENTO FÍSICO AERÓBIO REDUZ O RISCO CARDIOVASCULAR DE RATOS ESPONTANEAMENTE HIPERTENSOS.

Detalhes bibliográficos
Autor(a) principal: COSTA, Herikson Araujo
Data de Publicação: 2021
Tipo de documento: Tese
Idioma: por
Título da fonte: Biblioteca Digital de Teses e Dissertações da UFMA
Texto Completo: https://tedebc.ufma.br/jspui/handle/tede/tede/3687
Resumo: Introduction: systemic arterial hypertension (SAH), characterized by the maintenance of high blood pressure levels, is considered the main risk factor for the triggering of cardiovascular disorders (CVDs). Therefore, it is salutary to investigate new therapies, especially non- medications, that can assist in the treatment of SAH and reduce cardiovascular risks. In this context, carvacrol, a monoterpene classified as a major compound in oregano, appears as a promising option for use in the treatment of CVDs, since its anti-inflammatory, antioxidant, antihypertensive and cardioprotective properties are already known. Another non-drug therapy widely studied for the treatment of CVDs is aerobic physical training, which can provide modular effects on lipid parameters, blood pressure and cardiac remodeling. Objective: to investigate whether aerobic physical training enhances the reduction of cardiovascular risk in spontaneously hypertensive rats treated with 20 mg/kg of carvacrol. Method: the experimental design was composed of six groups, 1) normotensive control group (Wistar), 2) hypertensive control (SHR), 3) positive control treated with amlodipine (Aml-20mg), 4) group treated with carvacrol (Carv-20mg), 5) treated with exercise (Exer) and 6) treated with exercise and carvacrol (ExerCarv), who underwent four weeks of treatment and weekly heart rate, systolic, diastolic and mean blood pressure. Before and at the end of the treatment protocol, the animals were submitted to a test of maximum physical effort on a treadmill. At the end of the treatment, vascular reactivity tests were performed, in addition to biochemical measurements of blood glucose, urea, creatinine, AST, ALT, triglycerides, total cholesterol, HDL-C, LDL-C, VLDL- C, calculations of atherogenic indexes, weight organ relative and histopathological analysis of cardiac perivascular tissue. Results: the treated groups did not experience renal and hepatic toxicity, since there was a reduction in serum urea and AST levels. The proposed treatment program reduced blood pressure levels of hypertensive animals from the first week, with hypertension being controlled after four weeks of treatment. The ExerCarv group experienced greater magnitudes of BP reduction when compared to the other groups, including the group treated with amlodipine (ExerCarv: ∆ SBP = 88.17 ± 10.0 mmHg; ∆ DBP = 66.17 ± 31.89 mmHg; ∆ MAP = 73.5 ± 20.0 mmHg). We can still observe a decrease in vascular reactivity, with the treated groups developing less vascular tension (Emax) when exposed to cumulative concentrations of norepinephrine and calcium. The Carv-20mg group demonstrated a discreet effect on lipid variables, reducing only serum levels of triglycerides, LDL cholesterol and atherogenic indexes, while trained groups (Exer and ExerCarv) managed to modulate all lipid variables regardless of the use of carvacrol. It was also possible to observe a maintenance of the relative weight of the heart (g / 100g) (Wistar: 0.42 ± 0.03; SHR: 0.48 ± 0.03; Aml-20mg: 0.39 ± 0.03; Char -20mg: 0.41 ± 0.04; Exer: 0.42 ± 0.02 and ExerCarv: 0.41 ± 0.03), as well as changes in the level of cardiac tissue in the treated animals, with the animals in the group Untreated SHR, with hypertrophy of perivascular tissue and more swollen cardiomyocytes. Conclusion: four weeks of treatment with carvacrol (orally) or aerobic training, of SHR animals is efficient for regularization of BP, and the interaction between these therapies provides a greater magnitude of blood pressure reduction. We also concluded that aerobic physical training modulates the lipid variables associated with cardiovascular risk, regardless of the use of carvacrol. Finally, treatment with carvacrol and / or aerobic training preserves the cardiac muscle, preventing hypertrophy and tissue disorders related to injury to this organ by hypertension.
id UFMA_6515c3f598383fb0f926cc87242fd1b0
oai_identifier_str oai:tede2:tede/3687
network_acronym_str UFMA
network_name_str Biblioteca Digital de Teses e Dissertações da UFMA
repository_id_str 2131
spelling SALGADO FILHO, NatalinoRIBEIRO, Rachel MeloRIBEIRO, Rachel Melo RibeiroWANNER, Samuel PennaPAES, Antônio Marcus de AndradeLIBÉRIO, Rosane Nassar Meireles GuerraCOSTA, Herikson Araujo2022-06-14T19:35:20Z2021-03-25COSTA, Herikson Araujo. Terapia combinada de carvacrol com treinamento físico aeróbio reduz o risco cardiovascular de ratos espontaneamente hipertensos. 2021. 104 f. Tese( Programa de Pós-Graduação em Ciências da Saúde/CCBS) - Universidade Federal do Maranhão, São Luís, 2021.https://tedebc.ufma.br/jspui/handle/tede/tede/3687Introduction: systemic arterial hypertension (SAH), characterized by the maintenance of high blood pressure levels, is considered the main risk factor for the triggering of cardiovascular disorders (CVDs). Therefore, it is salutary to investigate new therapies, especially non- medications, that can assist in the treatment of SAH and reduce cardiovascular risks. In this context, carvacrol, a monoterpene classified as a major compound in oregano, appears as a promising option for use in the treatment of CVDs, since its anti-inflammatory, antioxidant, antihypertensive and cardioprotective properties are already known. Another non-drug therapy widely studied for the treatment of CVDs is aerobic physical training, which can provide modular effects on lipid parameters, blood pressure and cardiac remodeling. Objective: to investigate whether aerobic physical training enhances the reduction of cardiovascular risk in spontaneously hypertensive rats treated with 20 mg/kg of carvacrol. Method: the experimental design was composed of six groups, 1) normotensive control group (Wistar), 2) hypertensive control (SHR), 3) positive control treated with amlodipine (Aml-20mg), 4) group treated with carvacrol (Carv-20mg), 5) treated with exercise (Exer) and 6) treated with exercise and carvacrol (ExerCarv), who underwent four weeks of treatment and weekly heart rate, systolic, diastolic and mean blood pressure. Before and at the end of the treatment protocol, the animals were submitted to a test of maximum physical effort on a treadmill. At the end of the treatment, vascular reactivity tests were performed, in addition to biochemical measurements of blood glucose, urea, creatinine, AST, ALT, triglycerides, total cholesterol, HDL-C, LDL-C, VLDL- C, calculations of atherogenic indexes, weight organ relative and histopathological analysis of cardiac perivascular tissue. Results: the treated groups did not experience renal and hepatic toxicity, since there was a reduction in serum urea and AST levels. The proposed treatment program reduced blood pressure levels of hypertensive animals from the first week, with hypertension being controlled after four weeks of treatment. The ExerCarv group experienced greater magnitudes of BP reduction when compared to the other groups, including the group treated with amlodipine (ExerCarv: ∆ SBP = 88.17 ± 10.0 mmHg; ∆ DBP = 66.17 ± 31.89 mmHg; ∆ MAP = 73.5 ± 20.0 mmHg). We can still observe a decrease in vascular reactivity, with the treated groups developing less vascular tension (Emax) when exposed to cumulative concentrations of norepinephrine and calcium. The Carv-20mg group demonstrated a discreet effect on lipid variables, reducing only serum levels of triglycerides, LDL cholesterol and atherogenic indexes, while trained groups (Exer and ExerCarv) managed to modulate all lipid variables regardless of the use of carvacrol. It was also possible to observe a maintenance of the relative weight of the heart (g / 100g) (Wistar: 0.42 ± 0.03; SHR: 0.48 ± 0.03; Aml-20mg: 0.39 ± 0.03; Char -20mg: 0.41 ± 0.04; Exer: 0.42 ± 0.02 and ExerCarv: 0.41 ± 0.03), as well as changes in the level of cardiac tissue in the treated animals, with the animals in the group Untreated SHR, with hypertrophy of perivascular tissue and more swollen cardiomyocytes. Conclusion: four weeks of treatment with carvacrol (orally) or aerobic training, of SHR animals is efficient for regularization of BP, and the interaction between these therapies provides a greater magnitude of blood pressure reduction. We also concluded that aerobic physical training modulates the lipid variables associated with cardiovascular risk, regardless of the use of carvacrol. Finally, treatment with carvacrol and / or aerobic training preserves the cardiac muscle, preventing hypertrophy and tissue disorders related to injury to this organ by hypertension.Introdução: a hipertensão arterial sistêmica (HAS), caracterizada pela sustentação de níveis elevados de pressão arterial, é considerada o principal fator de risco para o desencadeamento de desordens cardiovasculares (DCVs). Portanto, é salutar a investigação de novas terapias, principalmente não-medicamentosas, que possam auxiliar no tratamento da HAS e redução dos riscos cardiovasculares. Nesse contexto, o carvacrol, monoterpeno classificado como composto majoritário no orégano, surge como uma opção promissora para uso no tratamento de DCVs, uma vez que já são conhecidas suas propriedades anti-inflamatória, antioxidante, anti- hipertensiva e cardioprotetora. Outra terapia não medicamentosa bastante estudada para o tratamento de DCVs, é o treinamento físico aeróbio, que pode proporcionar efeitos modulares sobre os parâmetros lipídicos, pressão arterial e remodelamento cardíaco. Objetivo: investigar se o treinamento físico aeróbio potencializa a redução do risco cardiovascular em ratos espontaneamente hipertensos tratados com 20 mg/kg/dia de carvacrol. Método: o delineamento experimental foi composto por seis grupos, 1) grupo controle normotenso (Wistar), 2) controle hipertensivo (SHR), 3) controle positivo tratado com anlodipina (Anl-20mg), 4) grupo tratado com carvacrol (Carv-20mg), 5) tratado com exercício (Exer) e 6) tratados com exercícios e carvacrol (ExerCarv), que realizaram quatro semanas de tratamento e registro semanal de frequência cardíaca, pressão arterial sistólica, diastólica e média. Antes e ao final do protocolo de tratamento, os animais foram submetidos a realização de um teste de esforço físico máximo em esteira ergométrica. Ao final do tratamento, foram realizados testes de reatividade vascular, além de medidas bioquímicas de glicemia, uréia, creatinina, AST, ALT, triglicerídeos, colesterol total, HDL-C, LDL-C, VLDL-C, cálculos de índices aterogênicos, peso relativo do órgão e análise histopatológica do tecido perivascular cardíaco. Resultados: os grupos tratados não experimentaram toxidade renal e hepática, uma vez que houve redução dos níveis séricos de ureia e AST. O programa de tratamento proposto reduziu desde a primeira semana os níveis pressóricos dos animais hipertensos, sendo a hipertensão controlada após quatro semanas de tratamento. O grupo ExerCarv experimentou maiores magnitudes de redução da PA, quando comparado aos demais grupos, inclusive do grupo tratado com anlodipina (ExerCarv: ∆ PAS = 88,17 ± 10,0 mmHg; ∆ PAD = 66,17 ± 31,89 mmHg; ∆ PAM = 73,5 ± 20,0 mmHg). Ainda podemos observar uma diminuição da reatividade vascular, com os grupos tratados desenvolvendo menos tensão vascular (Emax) ao serem expostos a concentrações cumulativas de noradrenalina e cálcio. O grupo Carv-20mg demonstrou um efeito discreto sobre as variáveis lipídicas, reduzindo apenas os níveis séricos de triglicerídeos, LDL colesterol e índices aterogênicos, enquanto os grupos treinados (Exer e ExerCarv) conseguiram modular todas as variáveis lipídicas independente do uso de carvacrol. Também foi possível observar uma manutenção do peso relativo do coração (g/100g) (Wistar: 0,42 ± 0,03; SHR: 0,48 ± 0,03; Anl- 20mg: 0,39 ± 0,03; Carv-20mg: 0,41 ± 0,04; Exer: 0,42 ± 0,02 e ExerCarv: 0,41 ± 0,03), bem como de alterações a nível de tecido cardíaco nos animais tratados, com os animais do grupo SHR não tratado, apresentando hipertrofia do tecido perivascular e cardiomiócitos mais edemaciados. Conclusão: quatro semanas de tratamento com carvacrol (via oral) ou treinamento aeróbio, de animais SHR é eficiente para regularização da PA, sendo que a interação entre essas terapias proporciona uma maior magnitude de redução dos níveis pressóricos. Concluímos ainda que o treinamento físico aeróbio modula as variáveis lipídicas associadas ao risco cardiovascular, independente do uso de carvacrol. Por fim, o tratamento com carvacrol e/ou treinamento aeróbio preserva o músculo cardíaco, prevenindo de hipertrofia e desarranjos tissulares relacionados a lesão desse órgão pela hipertensão.Submitted by Maria Aparecida (cidazen@gmail.com) on 2022-06-14T19:35:20Z No. of bitstreams: 1 TESE- Heriksonvec.pdf: 42308909 bytes, checksum: 0f6120ebcc47537152cb7f85e94d6a23 (MD5)Made available in DSpace on 2022-06-14T19:35:20Z (GMT). No. of bitstreams: 1 TESE- Heriksonvec.pdf: 42308909 bytes, checksum: 0f6120ebcc47537152cb7f85e94d6a23 (MD5) Previous issue date: 2021-03-25FAPEMAapplication/pdfporUniversidade Federal do MaranhãoPROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE/CCBSUFMABrasilDEPARTAMENTO DE MEDICINA I/CCBSTreinamento físico aeróbio;Carvacrol;Hipertensão;Risco CardiovascularAerobic physical training;Carvacrol;Hypertension and cardiovascular riskCardiologiaTERAPIA COMBINADA DE CARVACROL COM TREINAMENTO FÍSICO AERÓBIO REDUZ O RISCO CARDIOVASCULAR DE RATOS ESPONTANEAMENTE HIPERTENSOS.COMBINED CARVACROL THERAPY WITH TRAINING AEROBIC PHYSICS REDUCES CARDIOVASCULAR RISK IN RATS SPONTANEOUSLY HYPERTENSIVE.info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisinfo:eu-repo/semantics/openAccessreponame:Biblioteca Digital de Teses e Dissertações da UFMAinstname:Universidade Federal do Maranhão (UFMA)instacron:UFMAORIGINALTESE- Heriksonvec.pdfTESE- Heriksonvec.pdfapplication/pdf42308909http://tedebc.ufma.br:8080/bitstream/tede/3687/2/TESE-+Heriksonvec.pdf0f6120ebcc47537152cb7f85e94d6a23MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-82255http://tedebc.ufma.br:8080/bitstream/tede/3687/1/license.txt97eeade1fce43278e63fe063657f8083MD51tede/36872022-06-14 16:35:20.823oai:tede2: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Biblioteca Digital de Teses e Dissertaçõeshttps://tedebc.ufma.br/jspui/PUBhttp://tedebc.ufma.br:8080/oai/requestrepositorio@ufma.br||repositorio@ufma.bropendoar:21312022-06-14T19:35:20Biblioteca Digital de Teses e Dissertações da UFMA - Universidade Federal do Maranhão (UFMA)false
dc.title.por.fl_str_mv TERAPIA COMBINADA DE CARVACROL COM TREINAMENTO FÍSICO AERÓBIO REDUZ O RISCO CARDIOVASCULAR DE RATOS ESPONTANEAMENTE HIPERTENSOS.
dc.title.alternative.eng.fl_str_mv COMBINED CARVACROL THERAPY WITH TRAINING AEROBIC PHYSICS REDUCES CARDIOVASCULAR RISK IN RATS SPONTANEOUSLY HYPERTENSIVE.
title TERAPIA COMBINADA DE CARVACROL COM TREINAMENTO FÍSICO AERÓBIO REDUZ O RISCO CARDIOVASCULAR DE RATOS ESPONTANEAMENTE HIPERTENSOS.
spellingShingle TERAPIA COMBINADA DE CARVACROL COM TREINAMENTO FÍSICO AERÓBIO REDUZ O RISCO CARDIOVASCULAR DE RATOS ESPONTANEAMENTE HIPERTENSOS.
COSTA, Herikson Araujo
Treinamento físico aeróbio;
Carvacrol;
Hipertensão;
Risco Cardiovascular
Aerobic physical training;
Carvacrol;
Hypertension and cardiovascular risk
Cardiologia
title_short TERAPIA COMBINADA DE CARVACROL COM TREINAMENTO FÍSICO AERÓBIO REDUZ O RISCO CARDIOVASCULAR DE RATOS ESPONTANEAMENTE HIPERTENSOS.
title_full TERAPIA COMBINADA DE CARVACROL COM TREINAMENTO FÍSICO AERÓBIO REDUZ O RISCO CARDIOVASCULAR DE RATOS ESPONTANEAMENTE HIPERTENSOS.
title_fullStr TERAPIA COMBINADA DE CARVACROL COM TREINAMENTO FÍSICO AERÓBIO REDUZ O RISCO CARDIOVASCULAR DE RATOS ESPONTANEAMENTE HIPERTENSOS.
title_full_unstemmed TERAPIA COMBINADA DE CARVACROL COM TREINAMENTO FÍSICO AERÓBIO REDUZ O RISCO CARDIOVASCULAR DE RATOS ESPONTANEAMENTE HIPERTENSOS.
title_sort TERAPIA COMBINADA DE CARVACROL COM TREINAMENTO FÍSICO AERÓBIO REDUZ O RISCO CARDIOVASCULAR DE RATOS ESPONTANEAMENTE HIPERTENSOS.
author COSTA, Herikson Araujo
author_facet COSTA, Herikson Araujo
author_role author
dc.contributor.advisor1.fl_str_mv SALGADO FILHO, Natalino
dc.contributor.advisor-co1.fl_str_mv RIBEIRO, Rachel Melo
dc.contributor.referee1.fl_str_mv RIBEIRO, Rachel Melo Ribeiro
dc.contributor.referee2.fl_str_mv WANNER, Samuel Penna
dc.contributor.referee3.fl_str_mv PAES, Antônio Marcus de Andrade
dc.contributor.referee4.fl_str_mv LIBÉRIO, Rosane Nassar Meireles Guerra
dc.contributor.author.fl_str_mv COSTA, Herikson Araujo
contributor_str_mv SALGADO FILHO, Natalino
RIBEIRO, Rachel Melo
RIBEIRO, Rachel Melo Ribeiro
WANNER, Samuel Penna
PAES, Antônio Marcus de Andrade
LIBÉRIO, Rosane Nassar Meireles Guerra
dc.subject.por.fl_str_mv Treinamento físico aeróbio;
Carvacrol;
Hipertensão;
Risco Cardiovascular
topic Treinamento físico aeróbio;
Carvacrol;
Hipertensão;
Risco Cardiovascular
Aerobic physical training;
Carvacrol;
Hypertension and cardiovascular risk
Cardiologia
dc.subject.eng.fl_str_mv Aerobic physical training;
Carvacrol;
Hypertension and cardiovascular risk
dc.subject.cnpq.fl_str_mv Cardiologia
description Introduction: systemic arterial hypertension (SAH), characterized by the maintenance of high blood pressure levels, is considered the main risk factor for the triggering of cardiovascular disorders (CVDs). Therefore, it is salutary to investigate new therapies, especially non- medications, that can assist in the treatment of SAH and reduce cardiovascular risks. In this context, carvacrol, a monoterpene classified as a major compound in oregano, appears as a promising option for use in the treatment of CVDs, since its anti-inflammatory, antioxidant, antihypertensive and cardioprotective properties are already known. Another non-drug therapy widely studied for the treatment of CVDs is aerobic physical training, which can provide modular effects on lipid parameters, blood pressure and cardiac remodeling. Objective: to investigate whether aerobic physical training enhances the reduction of cardiovascular risk in spontaneously hypertensive rats treated with 20 mg/kg of carvacrol. Method: the experimental design was composed of six groups, 1) normotensive control group (Wistar), 2) hypertensive control (SHR), 3) positive control treated with amlodipine (Aml-20mg), 4) group treated with carvacrol (Carv-20mg), 5) treated with exercise (Exer) and 6) treated with exercise and carvacrol (ExerCarv), who underwent four weeks of treatment and weekly heart rate, systolic, diastolic and mean blood pressure. Before and at the end of the treatment protocol, the animals were submitted to a test of maximum physical effort on a treadmill. At the end of the treatment, vascular reactivity tests were performed, in addition to biochemical measurements of blood glucose, urea, creatinine, AST, ALT, triglycerides, total cholesterol, HDL-C, LDL-C, VLDL- C, calculations of atherogenic indexes, weight organ relative and histopathological analysis of cardiac perivascular tissue. Results: the treated groups did not experience renal and hepatic toxicity, since there was a reduction in serum urea and AST levels. The proposed treatment program reduced blood pressure levels of hypertensive animals from the first week, with hypertension being controlled after four weeks of treatment. The ExerCarv group experienced greater magnitudes of BP reduction when compared to the other groups, including the group treated with amlodipine (ExerCarv: ∆ SBP = 88.17 ± 10.0 mmHg; ∆ DBP = 66.17 ± 31.89 mmHg; ∆ MAP = 73.5 ± 20.0 mmHg). We can still observe a decrease in vascular reactivity, with the treated groups developing less vascular tension (Emax) when exposed to cumulative concentrations of norepinephrine and calcium. The Carv-20mg group demonstrated a discreet effect on lipid variables, reducing only serum levels of triglycerides, LDL cholesterol and atherogenic indexes, while trained groups (Exer and ExerCarv) managed to modulate all lipid variables regardless of the use of carvacrol. It was also possible to observe a maintenance of the relative weight of the heart (g / 100g) (Wistar: 0.42 ± 0.03; SHR: 0.48 ± 0.03; Aml-20mg: 0.39 ± 0.03; Char -20mg: 0.41 ± 0.04; Exer: 0.42 ± 0.02 and ExerCarv: 0.41 ± 0.03), as well as changes in the level of cardiac tissue in the treated animals, with the animals in the group Untreated SHR, with hypertrophy of perivascular tissue and more swollen cardiomyocytes. Conclusion: four weeks of treatment with carvacrol (orally) or aerobic training, of SHR animals is efficient for regularization of BP, and the interaction between these therapies provides a greater magnitude of blood pressure reduction. We also concluded that aerobic physical training modulates the lipid variables associated with cardiovascular risk, regardless of the use of carvacrol. Finally, treatment with carvacrol and / or aerobic training preserves the cardiac muscle, preventing hypertrophy and tissue disorders related to injury to this organ by hypertension.
publishDate 2021
dc.date.issued.fl_str_mv 2021-03-25
dc.date.accessioned.fl_str_mv 2022-06-14T19:35:20Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv COSTA, Herikson Araujo. Terapia combinada de carvacrol com treinamento físico aeróbio reduz o risco cardiovascular de ratos espontaneamente hipertensos. 2021. 104 f. Tese( Programa de Pós-Graduação em Ciências da Saúde/CCBS) - Universidade Federal do Maranhão, São Luís, 2021.
dc.identifier.uri.fl_str_mv https://tedebc.ufma.br/jspui/handle/tede/tede/3687
identifier_str_mv COSTA, Herikson Araujo. Terapia combinada de carvacrol com treinamento físico aeróbio reduz o risco cardiovascular de ratos espontaneamente hipertensos. 2021. 104 f. Tese( Programa de Pós-Graduação em Ciências da Saúde/CCBS) - Universidade Federal do Maranhão, São Luís, 2021.
url https://tedebc.ufma.br/jspui/handle/tede/tede/3687
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal do Maranhão
dc.publisher.program.fl_str_mv PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE/CCBS
dc.publisher.initials.fl_str_mv UFMA
dc.publisher.country.fl_str_mv Brasil
dc.publisher.department.fl_str_mv DEPARTAMENTO DE MEDICINA I/CCBS
publisher.none.fl_str_mv Universidade Federal do Maranhão
dc.source.none.fl_str_mv reponame:Biblioteca Digital de Teses e Dissertações da UFMA
instname:Universidade Federal do Maranhão (UFMA)
instacron:UFMA
instname_str Universidade Federal do Maranhão (UFMA)
instacron_str UFMA
institution UFMA
reponame_str Biblioteca Digital de Teses e Dissertações da UFMA
collection Biblioteca Digital de Teses e Dissertações da UFMA
bitstream.url.fl_str_mv http://tedebc.ufma.br:8080/bitstream/tede/3687/2/TESE-+Heriksonvec.pdf
http://tedebc.ufma.br:8080/bitstream/tede/3687/1/license.txt
bitstream.checksum.fl_str_mv 0f6120ebcc47537152cb7f85e94d6a23
97eeade1fce43278e63fe063657f8083
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Biblioteca Digital de Teses e Dissertações da UFMA - Universidade Federal do Maranhão (UFMA)
repository.mail.fl_str_mv repositorio@ufma.br||repositorio@ufma.br
_version_ 1809926202399391744